Intensity Therapeutics, Inc. (INTS) Analysis

Intensity Therapeutics, recently given an average price target of $3 by four analysts. Intensity Therapeutics (Nasdaq: INTS) is a **late‑stage clinical biotechnology company** based in Shelton, Connecticut. The firm is advancing **INT230‑6**, a proprietary intratumoral immuno-oncology therapy formulated on its **DfuseRx™ platform**—a system combining two cytotoxic agents (cisplatin, vinblastine) with a penetration-enhancing amphiphile (SHAO), enabling deep diffusion into solid tumors and trigge...